A股異動 | 寶豐能源漲約4% 年產25萬噸!EVA項目預計2023年一季度投產
格隆匯11月18日丨寶豐能源半日收漲約4%,報15.88元,高見16.15元創一個半月新高,總市值1165億元。近日,寶豐能源在投資者互動平台表示,25萬EVA產能預計2023年一季度投產。據悉,寶豐能源寧東三期項目配套建設25萬噸/年EVA裝置(選用巴賽爾高壓管式EVA技術),寧東四期烯烴項目包含25萬噸/年EVA,可生產VA含量0-30%的EVA產品,可廣泛用於高端包裝薄膜、電線電纜、發泡鞋材、熱熔膠、EVA玩具、功能性棚膜和光伏封裝;其中VA含量20%-30%的EVA可用於光伏膠膜。寧東三期25萬噸,四期25萬噸/年EVA項目全部投產後,寶豐能源EVA產能將達到50萬噸/年。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.